Unlock instant, AI-driven research and patent intelligence for your innovation.

Secondary binding site of dipeptidyl peptidase IV (DPIV)

a dipeptidyl peptidase and binding site technology, applied in the field of secondary binding site of dipeptidyl peptidase iv, can solve the problems of low relative insulin level, gradual loss of insulin secretory capacity, and disease, and achieve the effect of increasing substrate dependent dp iv-selectivity and minimizing side reactions

Inactive Publication Date: 2005-08-11
PROSIDION LIMITED
View PDF28 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a method to identify the specific site in the DP IV protein or DP IV-like enzymes that modulate the substrate specificity of DP IV. This allows for the development of new compounds that can regulate the substrate specificity of DP IV and be used for the treatment of various target diseases such as diabetes, metabolic disorders, skin diseases, autoimmune diseases, inflammatory conditions, and more. The invention also provides a computer-generated model of DP IV and specific compounds that can modify the DP IV-catalyzed truncation of substrates with high selectivity, minimizing side reactions and potential side effects after complete inhibition of DP IV activity."

Problems solved by technology

Thereafter, insulin secretory capacity is gradually lost (over several years).
However, insulin levels are low relative to the magnitude of insulin resistance and ambient glucose levels.
Moreover, if the level of hyperglycemia is insufficient to produce symptoms, the disease may become evident only after complications develop.
However, a small subgroup of patients are difficult to classify, that is, they display features common to both type 1 and 2 diabetes.
Such patients are commonly non-obese and have reduced insulin secretory capacity that is not sufficient to make them ketosis prone.
Many initially respond to oral agents but, with time , require insulin.
Both conditions are associated with an increased risk for cardiovascular disease, but do not produce the classic symptoms or the microvascular and neuropathic complications associated with diabetes mellitus.
The data suggest that subjects with IGM , in particular, those with impaired glucose tolerance (IGT), do not always develop diabetes, but whether they are diabetic or not, they are, nonetheless, at high risk for cardiovascular morbidity and mortality.
This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in the liver.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Secondary binding site of dipeptidyl peptidase IV (DPIV)
  • Secondary binding site of dipeptidyl peptidase IV (DPIV)
  • Secondary binding site of dipeptidyl peptidase IV (DPIV)

Examples

Experimental program
Comparison scheme
Effect test

example 1

Determination of the Half-Life (t1 / 2)

[0456] Matrix-assisted laser-desorption ionization time of flight mass spectrometry (MALDI-TOF MS) experiments were carried out at 30° C. at pH 7.6 in 0.1 M Tris / HCl (Sigma-Aldrich, Deisenhofen, Germany) buffer with 25 μM peptide solution. The degradation fate of peptides was measured by monitoring the signal intensity of the pseudomolecular ion peaks of parent peptides and N-terminal shorted peptides versus time when incubated with 40 mU procine DP IV, recombinant human DP IV or serum DP IV activity. The enzyme was preincubated with hexapeptide TFTSDY or TFTDDY or the heptapeptide H-Ser-D-Glu-Thr-Gly-D-Val-D-Lys-D-Val-OH (15 min, 30° C., 0,016M, 1:1 with DP IV, the concentration of the hexapeptide or the heptapeptide in the reaction mixture was 160 μM). As control served the preincubation of DP IV with 0.01M Tris-buffer (Sigma-Aldrich, Deisenhofen, Germany). The mass spectrometer employed was a Hewlett-Packard G2025 model with a linear time of...

example 2

Determination of Ki:

[0467] In order to measure the inhibition constant Ki a photometric assay was used The peptides were measured as competitors of the standard substrate GP-4-Nitroanilide. Three different substrate concentrations (0.4 mM to 0.05 mM) were combined with 8 different competitor concentrations (0.5 mM to 2 μM). The reaction was started by addition of 3.5 nM DP IV. Experiments were carried out under standard conditions: 30° C. in pH 7.6 40 mM HEPES (Sigma-Aldrich) buffer. Nitroaniline production was monitored using a HTS 7000+ microplate reader (PerkinElmer, Uberlingen, Germany). The Ki-values were calculated via non-linear regression using the enzyme kinetic program Grafit 4.016 (Erithacus Ltd, UK).

[0468] For a reversible competitive inhibition is to assumed: vi=Vmax*Km[S]+Km⁡(1+[I]Ki)

[0469] Legend. [0470] [I] inhibitor concentration [0471] Ki inhibition constant

example 3

MALDI-TOF Approach

[0472] In order to investigate directly the influence of the test compounds TFTSDY, TFTDDY and H-Ser-D-Glu-Thr-Gly-D-Val-D-Lys-D-Val-OH on the DP IV-catalyzed peptide hydrolysis the MALDI-TOF assay was used.

[0473] As described before (determination of t1 / 2) DP IV and the test compounds were preincubated and the reaction was started by adding the enzyme / hexapeptide mixture to substrate / buffer mix. The control reaction mixture consisted of buffer, enzyme and substrate. From the curves of the first order exponential the initial rate (vi) for the control and the reversible inhibited reaction was calculated.

[0474] For the uninfluenced reaction the Michaelis-Menten-equation was used. [0475] Vi was calculated from plotting the relative substrate concentration versus time. [0476] Km is given, also the substrate concentration. vi=Vmax*KmKm+[S]

[0477] For the reversible inhibited reaction the following reaction was used to calculate Ki: vi=Vmax*Km[S]+Km⁡(1+[I]Ki)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
molecular weightaaaaaaaaaa
structureaaaaaaaaaa
Login to View More

Abstract

The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

Description

CROSS REFERENCES TO RELATED APPLICATIONS [0001] This application claims priority of U.S. patent application Ser. No. 10 / 246,817, filed Sep. 18, 2002 and also claims priority of U.S. Provisional Patent Application Ser. No. 60 / 443,417 filed Jan. 29, 2003 both of which are incorporated herein by reference in their entirety.FIELD OF THE APPLICATION [0002] The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship with any type of substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). [0003] The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV. [0004] Furthermore, the present invention provides a method for treating DP IV mediated disorders, selected from but not restricted to, impaired glucose tolerance, glucosuria, lipid disorders, dyslipidemia, hyperlipidaemia, hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/155A61K31/175A61K31/401A61K31/455A61K31/704A61K38/00A61K38/08A61K38/22A61K38/28A61P3/00C07K7/06C12Q1/37
CPCA61K31/401A61K38/00G01N2500/04C12Q1/37C07K7/06A61P3/00
Inventor KUHN-WACHE, KERSTINBAR, JOACHIMDEMUTH, HANS-ULRICHHOFFMANN, TORSTENHEISER, ULRICHBRANDT, WOLFGANG
Owner PROSIDION LIMITED